Top 10 Immunology Drugs to Watch in 2024AbbVieExplore the top 10 best-selling immunology drugs of 2023, including Humira, Dupixent, Stelara, and more. Discover how these innovative therapies are shaping the market, driving clinical breakthroughs, and overcoming competitive challenges.
AbbVie Q3 2024 Financial statementsFinancial statementsIn Q3 2024, AbbVie reported net revenues of $14.460 billion, a 3.8% year-on-year increase. Skyrizi surged by 50.8% to $3.205 billion, offsetting Humira's decline due to generics. Diverse segments, including Oncology and Neuroscience, showed solid growth, while strategic acquisitions.
MNC Profiles: Who Values ??the Chinese Market Most?AstraZenecaExplore the competitive landscape of multinational pharmaceutical companies (MNCs) in China’s booming healthcare market. Delves into MNC revenue trends, strategies, and insights, highlighting which companies value the Chinese market most.
FDA approves AbbVie's 24-hour subcutaneous infusion therapyAbbVieThe FDA has approved AbbVie’s VYALEV (ABBV-951), a 24-hour continuous subcutaneous infusion therapy for advanced Parkinson's disease. This first-of-its-kind treatment, based on levodopa, offers significant improvements in motor fluctuations and prolongs "on" time with fewer complications.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
